Revolution Medicines, Inc. (NASDAQ: RVMD) is a Healthcare company (Biotechnology) with a market capitalization of $35.3B. The Maz Rating grades it against the other companies in its sector.
Revolution Medicines, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $163.02, Revolution Medicines, Inc. trades at 182.7x sales and 14.9x book value. Over the last twelve months it generated about $193M of revenue and a net loss of $1.9B. It runs a gross margin of 95.2%, an operating margin of -853.0% and a net margin of -946.8%. It shows return on equity of -91.9%, return on invested capital of -43.9% and a free cash flow yield of -4.0%. On the balance sheet: a debt-to-equity ratio of 0.27 and a current ratio of 8.36. Over the past 52 weeks the share price ranged from $67.86 to $224.31, with a beta of 1.43.
Revolution Medicines, Inc. does not currently pay a dividend.
25 Wall Street analyst ratings cover the stock: 1 Strong Buy, 22 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Revolution Medicines, Inc. (RVMD) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 1.17% / 30% · (Cash+Inv) / Mkt Cap (36m) 8.75% / 30% · Interest income / Revenue 19.1% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 1.17% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 8.75% / 33% · Receivables / Mkt Cap (36m) 0.55% / 49% · Interest income / Revenue 19.1% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 1.17% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 8.75% / 33.33% · Receivables / Mkt Cap (24m) 0.55% / 33.33% · Interest income / Revenue 19.1% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 10.6% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 87.1% / 33.33% · Receivables / Avg Assets (4Q) 1.74% / 33.33% · Interest income / Revenue 19.1% / 5% | Fail |
| FTSE | Debt / Total Assets 11.3% / 33.33% · (Cash+ST Inv) / Total Assets 84.8% / 33.33% · (Cash+Recv) / Total Assets 90.2% / 33.33% · Interest income / Revenue 19.1% / 5% | Fail |
No. As of September 2026, Revolution Medicines, Inc. (RVMD) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Revolution Medicines, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 19.1% of each dividend: Revolution Medicines, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.